Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and ...
MarketBeat on MSN1mon
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we ...
Hosted on MSN1mon
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President, ...
Business Insider India5y
Pharma CEOs got into a heated debate over why people hate the industry
The panel featured Gilead CEO John Milligan, Pfizer CEO Ian Read, incoming Eli Lilly CEO David Ricks, Astellas Americas President Jim Robinson, and Regeneron CEO Leonard Schleifer. After some ...